196 related articles for article (PubMed ID: 26241816)
1. Patient-reported sexual toxicity after radiation therapy in long-term prostate cancer survivors.
Olsson CE; Alsadius D; Pettersson N; Tucker SL; Wilderäng U; Johansson KA; Steineck G
Br J Cancer; 2015 Sep; 113(5):802-8. PubMed ID: 26241816
[TBL] [Abstract][Full Text] [Related]
2. Patient-reported genitourinary toxicity for long-term prostate cancer survivors treated with radiation therapy.
Olsson CE; Pettersson N; Alsadius D; Wilderäng U; Tucker SL; Johansson KA; Steineck G
Br J Cancer; 2013 May; 108(10):1964-70. PubMed ID: 23632483
[TBL] [Abstract][Full Text] [Related]
3. Acute genitourinary toxicity after high-dose-rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Ito K; Saitoh J; Noda SE; Harashima K; Sakurai H; Nakayama Y; Yamamoto T; Suzuki K; Nakano T; Niibe H
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):463-71. PubMed ID: 16168838
[TBL] [Abstract][Full Text] [Related]
4. Urethral pain among prostate cancer survivors 1 to 14 years after radiation therapy.
Pettersson N; Olsson C; Tucker SL; Alsadius D; Wilderäng U; Johansson KA; Steineck G
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):e29-37. PubMed ID: 23237005
[TBL] [Abstract][Full Text] [Related]
5. Temporal patterns of selected late toxicities in patients treated with brachytherapy or brachytherapy plus external beam radiation for prostate adenocarcinoma.
Buckstein M; Kerns S; Forysthe K; Stone NN; Stock RG
BJU Int; 2013 Mar; 111(3 Pt B):E43-7. PubMed ID: 23046084
[TBL] [Abstract][Full Text] [Related]
6. The burden of overtreatment: comparison of toxicity between single and combined modality radiation therapy among low risk prostate cancer patients.
Jiang R; Tomaszewski JJ; Ward KC; Uzzo RG; Canter DJ
Can J Urol; 2015 Feb; 22(1):7648-55. PubMed ID: 25694014
[TBL] [Abstract][Full Text] [Related]
7. Prevalence and Predicting Factors for Commonly Neglected Sexual Side Effects to External-Beam Radiation Therapy for Prostate Cancer.
Frey A; Pedersen C; Lindberg H; Bisbjerg R; Sønksen J; Fode M
J Sex Med; 2017 Apr; 14(4):558-565. PubMed ID: 28258954
[TBL] [Abstract][Full Text] [Related]
8. Favourable long-term outcomes with brachytherapy-based regimens in men ≤60 years with clinically localized prostate cancer.
Kollmeier MA; Fidaleo A; Pei X; Cohen G; Zaider M; Mo Q; Cox B; Yamada Y; Zelefsky MJ
BJU Int; 2013 Jun; 111(8):1231-6. PubMed ID: 23551568
[TBL] [Abstract][Full Text] [Related]
9. Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer.
Burri RJ; Stone NN; Unger P; Stock RG
Int J Radiat Oncol Biol Phys; 2010 Aug; 77(5):1338-44. PubMed ID: 20138442
[TBL] [Abstract][Full Text] [Related]
10. Acute genitourinary toxicity after high dose rate (HDR) brachytherapy combined with hypofractionated external-beam radiation therapy for localized prostate cancer: Second analysis to determine the correlation between the urethral dose in HDR brachytherapy and the severity of acute genitourinary toxicity.
Akimoto T; Katoh H; Noda SE; Ito K; Yamamoto T; Kashiwagi B; Nakano T
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):472-8. PubMed ID: 16168839
[TBL] [Abstract][Full Text] [Related]
11. Patient-reported gastrointestinal symptoms among long-term survivors after radiation therapy for prostate cancer.
Alsadius D; Olsson C; Pettersson N; Tucker SL; Wilderäng U; Steineck G
Radiother Oncol; 2014 Aug; 112(2):237-43. PubMed ID: 25201126
[TBL] [Abstract][Full Text] [Related]
12. Combination external beam radiation and brachytherapy boost with androgen suppression for treatment of intermediate-risk prostate cancer: an initial report of CALGB 99809.
Hurwitz MD; Halabi S; Ou SS; McGinnis LS; Keuttel MR; Dibiase SJ; Small EJ
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(3):814-9. PubMed ID: 18407435
[TBL] [Abstract][Full Text] [Related]
13. Erectile function following brachytherapy, external beam radiotherapy, or radical prostatectomy in prostate cancer patients.
Putora PM; Engeler D; Haile SR; Graf N; Buchauer K; Schmid HP; Plasswilm L
Strahlenther Onkol; 2016 Mar; 192(3):182-9. PubMed ID: 26713323
[TBL] [Abstract][Full Text] [Related]
14. Long-term potency preservation following brachytherapy for prostate cancer.
Snyder KM; Stock RG; Buckstein M; Stone NN
BJU Int; 2012 Jul; 110(2):221-5. PubMed ID: 22734475
[TBL] [Abstract][Full Text] [Related]
15. Median 5 year follow-up of 125iodine brachytherapy as monotherapy in men agedGómez-Iturriaga Piña A; Crook J; Borg J; Lockwood G; Fleshner N
Urology; 2010 Jun; 75(6):1412-6. PubMed ID: 20035986
[TBL] [Abstract][Full Text] [Related]
16. Radiation Dose to the Penile Structures and Patient-Reported Sexual Dysfunction in Long-Term Prostate Cancer Survivors.
Thor M; Olsson CE; Oh JH; Alsadius D; Pettersson N; Deasy JO; Steineck G
J Sex Med; 2015 Dec; 12(12):2388-97. PubMed ID: 26564611
[TBL] [Abstract][Full Text] [Related]
17. The use of treatments for erectile dysfunction among survivors of prostate carcinoma.
Schover LR; Fouladi RT; Warneke CL; Neese L; Klein EA; Zippe C; Kupelian PA
Cancer; 2002 Dec; 95(11):2397-407. PubMed ID: 12436448
[TBL] [Abstract][Full Text] [Related]
18. [Clinical outcome of intermediate risk prostate cancer treated with iodine 125 monotherapy: The Hotel-Dieu of Quebec experience].
Zebentout O; Apardian R; Beaulieu L; Harel F; Martin AG; Vigneault E
Cancer Radiother; 2010 Jun; 14(3):183-8. PubMed ID: 20418145
[TBL] [Abstract][Full Text] [Related]
19. Brachytherapy improves biochemical failure-free survival in low- and intermediate-risk prostate cancer compared with conventionally fractionated external beam radiation therapy: a propensity score matched analysis.
Smith GD; Pickles T; Crook J; Martin AG; Vigneault E; Cury FL; Morris J; Catton C; Lukka H; Warner A; Yang Y; Rodrigues G
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(3):505-16. PubMed ID: 25596107
[TBL] [Abstract][Full Text] [Related]
20. Defining sexual outcomes after treatment for localized prostate carcinoma.
Schover LR; Fouladi RT; Warneke CL; Neese L; Klein EA; Zippe C; Kupelian PA
Cancer; 2002 Oct; 95(8):1773-85. PubMed ID: 12365027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
